Full Press Release Details
Alterity Therapeutics Limited (ASX: ATH) - Trading
The securities of Alterity Therapeutics Limited ( ATH')
will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities
will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 17 July 2024 or when the announcement
is released to the market.
| 15 July 2024 | Market Announcement 1/1 |
| ASX Limited | ASX Customer Service Centre 131 279 | asx.com.au |
Compliance Adviser, Listings Compliance (Melbourne)
Level 50, South Tower, Rialto 525 Collins St
| By email: | TradingHaltsMelbourne@asx.com.au |
| ListingsComplianceMelbourne@asx.com.au |
Request for a trading halt - Alterity Therapeutics
In accordance with ASX Listing Rule 17.1, Alterity Therapeutics
Limited (ASX: ATH, NASDAQ: ATHE) (the Company) requests that its securities be placed into an immediate trading halt pending an
announcement in relation to new data from an ATH434 clinical trial.
The Company requests that trading in its securities be halted
until after the expected announcement is made or until the market opens on Wednesday, 17 July 2024, whichever is the earlier.
The Company is not aware of any reason why this trading
halt request should not be granted or of any other information necessary to inform the market about the trading halt.
Please contact me if you require any further information.
Alterity Therapeutics Limited ABN
Level 14, 350 Collins Street, Melbourne,
T: +61 (0)3 9349 4906 | www.alteritytherapeutics.com